24.86
1.36%
-0.57
Precedente Chiudi:
$25.43
Aprire:
$25.59
Volume 24 ore:
9,827
Relative Volume:
0.04
Capitalizzazione di mercato:
$1.24B
Reddito:
-
Utile/perdita netta:
$-82.83M
Rapporto P/E:
-20.03
EPS:
-1.2413
Flusso di cassa netto:
$-72.22M
1 W Prestazione:
+0.66%
1M Prestazione:
-13.11%
6M Prestazione:
+9.54%
1 anno Prestazione:
+125.18%
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Nome
Enliven Therapeutics Inc
Settore
Industria
Telefono
720-647-8519
Indirizzo
6200 LOOKOUT ROAD, BOULDER
Confronta ELVN con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
ELVN | 24.80 | 1.24B | 0 | -82.83M | -72.22M | -1.2413 |
VRTX | 445.46 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 736.00 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 585.04 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 247.45 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 102.20 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2023-03-29 | Iniziato | Jefferies | Buy |
Enliven Therapeutics Inc Borsa (ELVN) Ultime notizie
Short Interest in Enliven Therapeutics, Inc. (NASDAQ:ELVN) Increases By 6.1% - MarketBeat
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Bought by First Turn Management LLC - MarketBeat
Robert W. Baird Issues Positive Forecast for Enliven Therapeutics (NASDAQ:ELVN) Stock Price - Defense World
Enliven Therapeutics has cash runway into late 2026 - BizWest
Robert W. Baird Forecasts Strong Price Appreciation for Enliven Therapeutics (NASDAQ:ELVN) Stock - MarketBeat
RA Capital Management, L.P. Reduces Stake in Enliven Therapeutics Inc. - GuruFocus.com
Citadel Advisors LLC Adjusts Stake in Enliven Therapeutics Inc - GuruFocus.com
COMMODORE CAPITAL LP Expands Stake in Enliven Therapeutics Inc - GuruFocus.com
Enliven Therapeutics Reports Q3 Results and Clinical Progress - TipRanks
Polar Capital Holdings Plc's Strategic Acquisition in Enliven Th - GuruFocus.com
Enliven Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
(ELVN) Investment Analysis and Advice - Stock Traders Daily
Enliven Therapeutics to Present at the Jefferies London Healthcare Conference - StockTitan
How to Take Advantage of moves in (ELVN) - Stock Traders Daily
Jones Trading Initiates Coverage of Enliven Therapeutics (ELVN) with Buy Recommendation - MSN
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Enliven Therapeutics CFO Benjamin Hohl sells shares worth $178,484 By Investing.com - Investing.com South Africa
Enliven Therapeutics CFO Benjamin Hohl sells shares worth $178,484 - Investing.com
Enliven Therapeutics (ELVN) Price Target Increased by 10.75% to 35.02 - MSN
Enliven Therapeutics CFO sells $24,422 in stock By Investing.com - Investing.com Australia
Enliven Therapeutics CFO sells $24,422 in stock - Investing.com
Enliven Therapeutics chief medical officer sells $24,482 in stock By Investing.com - Investing.com Canada
Enliven Therapeutics chief medical officer sells $24,482 in stock - Investing.com India
Enliven Therapeutics COO Anish Patel sells $21,482 in stock - Investing.com
Enliven Therapeutics COO Anish Patel sells $21,482 in stock By Investing.com - Investing.com Australia
Enliven Therapeutics' chief scientific officer sells $25,412 in stock By Investing.com - Investing.com Australia
Enliven Therapeutics CEO Kintz sells $27,722 in stock - Investing.com
Enliven Therapeutics' chief scientific officer sells $25,412 in stock - Investing.com India
Enliven Therapeutics director Heyman sells $47,104 in stock By Investing.com - Investing.com Australia
Enliven Therapeutics CEO Kintz sells $27,722 in stock By Investing.com - Investing.com Australia
Enliven Therapeutics director Heyman sells $47,104 in stock - Investing.com India
Anish Patel Sells 716 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock - MarketBeat
When (ELVN) Moves Investors should Listen - Stock Traders Daily
Enliven Therapeutics, Inc. (ELVN) Is a Great Choice for 'Trend' Investors, Here's Why - MSN
ELVN stock soars to 52-week high, reaching $28.66 By Investing.com - Investing.com Australia
Enliven Therapeutics (NASDAQ:ELVN) Reaches New 52-Week HighHere's Why - MarketBeat
Richard A. Heyman Sells 1,270 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock - MarketBeat
Enliven Therapeutics Inc [ELVN] Insider Lyssikatos Joseph P sells 37,878 Shares - Knox Daily
Enliven Therapeutics Inc (ELVN) stock analysis: A simple moving average approach - US Post News
Financial Metrics Check: Enliven Therapeutics Inc (ELVN)’s Ratios for Trailing Twelve Months - The Dwinnex
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Short Interest Update - MarketBeat
Enliven Therapeutics, Inc. Is a Great Choice for 'Trend' Investors, Here's Why - Benzinga
Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Sells 10,420 Shares of Stock - MarketBeat
Enliven Therapeutics executive sells over $1.4 million in company stock - Investing.com India
Enliven Therapeutics director sells over $290k in company stock - Investing.com
Enliven Therapeutics director sells over $290k in company stock By Investing.com - Investing.com UK
Enliven Therapeutics (NASDAQ:ELVN) Trading Down 5.6%What's Next? - MarketBeat
Enliven Therapeutics CEO sells over $840k in company stock - Investing.com
Enliven Therapeutics CFO sells over $300k in company stock By Investing.com - Investing.com South Africa
Enliven Therapeutics Inc Azioni (ELVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):